Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250544 | 0.89 | BCHE (0.42) | BCHESIGMAR1HRH1MAOBACHE | |
| SCHEMBL4241235 | 0.84 | FAAH (0.49) | BCHES1PR5S1PR1ACHEFAAH | |
| SCHEMBL1014404 | 0.78 | S1PR5 (0.50) | SIGMAR1S1PR5S1PR1FAAHFUCA1 | |
| SCHEMBL8222010 | 0.77 | NPFFR1 (0.49) | BCHESIGMAR1S1PR5S1PR1DRD2 | |
| SCHEMBL4250549 | 0.73 | FAAH (0.50) | BCHES1PR5ACHEFAAH | |
| SCHEMBL5434868 | 0.71 | FUCA1 (0.49) | BCHESIGMAR1S1PR5S1PR1ACHE | |
| SCHEMBL5105568 | 0.71 | CHRM3 (0.46) | S1PR5S1PR1FUCA1NPY5R | |
| SCHEMBL5105573 | 0.71 | CHRM3 (0.46) | S1PR5S1PR1FUCA1NPY5R | |
| SCHEMBL19971612 | 0.70 | BCHE (0.51) | BCHES1PR5S1PR1MAOBACHE | |
| SCHEMBL19971611 | 0.70 | BCHE (0.51) | BCHES1PR5S1PR1MAOBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | BCHE 258/4885SIGMAR1 317/4885S1PR5 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.